WESTMINSTER, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the quarter ended March 31, 2016, and provided a business update.
“We are grateful for the continuing support of the physicians, clinical investigators and patients participating in the GENETIC-AF trial evaluating GencaroTM as potentially the first genetically-targeted treatment for atrial fibrillation,” commented Dr. Michael Bristow, ARCA’s President and CEO. “Last month we reached the halfway mark in enrollment to have a sufficient number of patients for the DSMB Phase 2B interim efficacy analysis, the outcome of which we expect in the second quarter of 2017.
“We are grateful for the continuing support of the physicians, clinical investigators and patients participating in the GENETIC-AF trial evaluating GencaroTM as potentially the first genetically-targeted treatment for atrial fibrillation,” commented Dr. Michael Bristow, ARCA’s President and CEO. “Last month we reached the halfway mark in enrollment to have a sufficient number of patients for the DSMB Phase 2B interim efficacy analysis, the outcome of which we expect in the second quarter of 2017.
